Key Takeaways
- Strong quarter, demand intact: Revenue grew 41.9% YoY with ~85% of that growth coming from volume, while management sees no slowdown and describes capacity as "quite booked for the next year."
- Value-added mix is the margin engine: Contribution from CBE and stearin rose to ~75% of sales, driving PAT margin expansion of 114 bps YoY to 17.6%.
- Inventory build is seasonal, not structural: Inventory jumped to INR1,000 crores because shea procurement started early alongside seasonal sal and mango buying; management expects normalization through H2.
- Capex cycle is entering its heavy phase: Larger investment is expected in H2 and next fiscal year, with new capacities commissioning around Q3/Q4 FY28 and contributing gradually from FY29.
- What to watch next quarter: Whether the INR1,000 cr inventory converts to cash as promised, the pace of H2 capex deployment, and any update on Burkina Faso regulatory approvals.
Demand & Customer Environment
- No slowdown visible: Management stated products are in short supply and capacities are quite booked for the next year, with no order deferrals from global chocolate or cosmetic customers despite geopolitical uncertainty.
- Growth composition undisclosed: Growth is a mix of new customer additions from new geographies and higher uptake by existing customers, but management declined to share the exact split.
- CBE pricing delinked from cocoa: CBE prices are stable and have no direct linkage to cocoa butter price movements; renewed contracts are achieving cost-margin expectations.
Ekta Soni: "The product what we are manufacturing currently are short in supply only. We are not seeing any slowdown with respect to demand for our product portfolio. The demands are very healthy. Currently, our capacities are also quite booked for the next kind of year."
Margins & Profitability
- PAT margin expansion: PAT grew 51.8% YoY to INR81 crores, with PAT margin expanding 114 bps to 17.6%; H1 PAT margin expanded 213 bps to 18.5%.
- EBITDA margin band: Management sees 25%–27% as a currently comfortable EBITDA margin band, with modest quarter-to-quarter movements possible due to macroeconomic factors.
- Margin tailwinds ahead: Margins expected to improve gradually as new capacities ramp, driven by product mix changes, operating leverage, and economies of scale.
- Raw material cost pressure: Shea raw material cost increased due to higher freight on imports from West Africa, plus a general 5%–7% input-cost inflation; freight cost percentage was not disclosed on the call.
- Forex gain: H1 other income included INR15 crores in forex gains.
Capacity & Capex
- Current utilization: Operating at approximately 85% utilization on expanded capacity of 47,500 tons; management expects to reach 85%–90% for the existing setup.
- New capacity timeline: New capacities expected to commission around Q3/Q4 FY28, with gradual contribution from FY29 onwards or around Q4 FY28; utilization expected to begin at 40%–50%, reaching 85%–90% optimum over ~2–3 years.
- Capex spend profile: Larger chunk of investment expected in H2 or the coming fiscal year after design and engineering completion.
- Debottlenecking: 4,500 MTPA debottlenecking under planning in Q3; second unit debottlenecking still to be completed, expected by end of FY27.
- Solvent fractionation plant: Currently in planning and engineering stage; described as a complex project due to different needs for different wild crops; management will update when something substantially materializes.
- Asset turn expectation: Management expects asset turn of ~5x–7x from the business on optimum utilization, depending on product mix.
Backward Integration & Sourcing
- Burkina Faso project: Land has been acquired; regulatory approvals are awaited; project timelines expected towards Q3/Q4 of FY28; currently in critical phase of completing design and engineering in-house, with capex updates expected in coming quarters.
- West Africa footprint: Company has recently incorporated and expanded its footprint in the West African market; shea procurement for FY27 already aligned.
- Cost advantage modest: Management sees only a 2%–3% company-level cost advantage from the Africa backward integration project.
- Early shea procurement: Procurement started earlier this year in the normal course of business; nuts are seasonal so procurement timing can vary, and management declined to confirm whether elevated H1 inventory will be a recurring pattern.
Ashok Jain: "We see hardly 2%-3% company level, maybe we will get the advantage of this."
Balance Sheet & Working Capital
- Inventory build: Inventory rose to INR1,000 crores from INR728 crores in March because shea procurement started earlier alongside seasonal procurement of sal and mango seeds; this is raw material stock that will be converted and sold, with normalization expected by Q3/Q4.
- Operating cash outflow: H1 operating cash outflow of INR252 crores is a timing impact from inventory, not a reflection of the business.
- Receivables normalized: Receivables spiked ~82% from March 2026 levels because the figure captured the last 15 days of September revenue; remittances already received and normalized.
- Balance sheet strength: Net debt-to-equity improved to 0.04x from 0.38x at FY26-end; cash and equivalents at INR498 crores.
Leadership & Strategic Direction
- Leadership restructured: Mr. Mudit Kumar Singh appointed as Chairman; Mr. Deep Saraf as Managing Director; Mrs. Vinita Saraf as President, Business Excellence and Development; Mr. Ashish Saraf moved to President, Strategic Planning and Business Development.
- Purpose of change: Management framed the restructuring as giving every critical area a clear owner, not a change of direction.
- MD's four-pillar plan: Expand capacity, scale refining, premiumize the mix, expand globally.
- LATAM ramp-up: Facility progressing and currently fully booked with existing capacity; product has to go from Indian plant; gradual ramp-up expected over the next few quarters, maybe in a year or so.
Ashish Saraf: "A company at this stage deserves dedicated leadership for each part of the business rather than one team carrying every responsibility. This is the purpose of this change. It is not a change of direction, it is a step to give every critical area a clear owner."
Deep Saraf: "Our plan rests on four pillars: expand capacity, scale refining, premiumize the mix, expand globally."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Inventory normalization | Raw material inventory to convert and sell; working capital to normalize | Through H2 FY27 |
| Second unit debottlenecking | Completion of debottlenecking for the second unit | By end of FY27 |
| New capacity commissioning | New capacities to commission | Around Q3/Q4 FY28 |
| New capacity ramp | Utilization to begin at 40%–50%, reaching 85%–90% optimum | Over ~2–3 years from commissioning |
| Burkina Faso project | Project timelines expected | Towards Q3/Q4 of FY28 |
| LATAM ramp-up | Gradual ramp-up from Indian plant supply | Over the next few quarters, maybe a year or so |
| EBITDA margin band | Comfortable at 25%–27%, with modest quarterly movements possible | Ongoing |
| CBE and stearin mix | Contribution band expected to remain in 70%–80% range | With existing capacity |
| Annual price benefit | 5%–10% from inflation or other factors, contributing to sales mix | Annually |
| Capex spend profile | Larger chunk of investment expected | H2 FY27 and next fiscal year |
Key Metrics
| Metric | Q2 FY27 |
|---|---|
| Revenue | ₹459 cr, up 41.9% YoY from ₹323 cr |
| EBITDA | ₹118 cr, up 34.4% YoY |
| EBITDA margin | 25.8%, despite higher inbound freight costs and global macro events |
| Profit after tax | ₹81 cr, up 51.8% YoY |
| PAT margin | 17.6%, expanded 114 bps YoY |
| H1 FY27 revenue | ₹863 cr, up 40.8% YoY |
| H1 FY27 EBITDA margin | 26.0% |
| H1 FY27 PAT margin | 18.5%, expanded 213 bps YoY |
| H1 domestic-to-export revenue mix | 39:61 |
| Volume growth contribution to YoY revenue growth | ~85%, with 10%–15% from price realization |
| Value-added product contribution to total sales | ~75%, up from 65%–70% earlier |
| Plant utilization | ~85% on expanded capacity of 47,500 tons |
| Inventory | ₹1,000 cr as of 30 Sep 2026, up from ₹728 cr in Mar 2026, driven by early shea procurement alongside seasonal sal and mango procurement |
| Net debt-to-equity | 0.04x as of 30 Sep 2026, improved from 0.38x at end of FY26 |
| Cash and cash equivalents and other bank balances | ₹498 cr as of 30 Sep 2026 |
| H1 FY27 operating cash outflow | ₹252 cr, timing impact from inventory build |
| Capex invested so far | ₹70–75 cr toward current capex, with significant chunk expected in H2 FY27 |
| H1 FY27 other income | ₹25 cr, comprising ₹15 cr forex gain and ₹10 cr interest on FDR |